Exploratory analysis of frontline therapies in REVEL: A phase 3 trial of ramucirumab in NSCLC

At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomised phase 3 clinical trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage 4 non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

Year of Production:
Running Time:


Comments are closed.